Please assess the completion status of the following clinical trial:

Trial Title: Optimization of Vonoprazan--amoxicillin Dual Therapy for Eradicating Helicobacter Pyloriinfection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70, regardless of gender; HP positive in 13C/14C breath test or pathological test; HP eradication has never been performed in the past; Based on the consensus of helicobacter pylori in 2017, it conforms to the HP eradication guideline; The patient voluntarily signed the informed consent.~Exclusion Criteria:~* History of drug allergy in this study; Liver and kidney dysfunction; Cardiopulmonary insufficiency; History of malignant tumor; Taking clopidogrel, warfarin and other drugs simultaneously may affect CYP2C19 metabolism; Pregnant or lactating women; Patients with severe mental illness; Those planning pregnancy; Previous upper gastrointestinal surgery history; Participated in any other clinical investigator in the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- H-VA-dual-10 (Type: EXPERIMENTAL): 10 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)
- L-VA-dual-10 (Type: EXPERIMENTAL): 10 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 1000mg/ time, 2 times/day, oral)
- H-VA-dual-14 (Type: ACTIVE_COMPARATOR): 14 days(vonoprazan fumarate tablets 20 mg/time, 2 times/day, oral~+Amoxicillin 750mg/ time, 4 times/day, oral)

Based on this trial design, predict the completion outcome and termination type (if applicable).